MedPath

Study of hand fracture fixation with hand plate system

Phase 4
Conditions
Health Condition 1: S623- Fracture of other and unspecifiedmetacarpal bone
Registration Number
CTRI/2024/04/065090
Lead Sponsor
Auxein Medical Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Both male and female above 18 years to 65 years

2 Patients presenting to Orthopaedic emergency or OPD with Hand Fracture which need internal fixation will be included in the study

Exclusion Criteria

1 Any past or present evidence of infection of the treated joint

2 Physical conditions that would eliminate or tend to eliminate adequate implant support or delayed healing viz blood supply limitations poor skin quality previous or active infections sepsis metabolic diseases etc

3 Signs of any local inflammation

4 Patient susceptibility to allergic reaction to the components of the alloy the implant is manufactured from

5 Mental or neurological conditions which tend to pre empt the patients ability or willingness to restrict activities during the healing period viz Parkinsons disease chronic alcoholism Charcots joints drug abuse mental illness patient noncompliance etc

6 Patients having inadequate tissue coverage over the operative site

7 Patient having Foreign body sensitivity

8 Patient with compromised skin

9 Severe osteopenia and or osteoporosis or the presence of marked or rapid bone absorption metabolic bone disease cancer or any other tumor like condition of the bone which may compromise fixation

10 Patient who is pregnant or intends to become pregnant during the study

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1 Quality of bone union and deformity correction <br/ ><br> <br/ ><br>2 Improvement in ASSH TAF scaleTimepoint: 6 weeks, 3,6, and 12 Months
Secondary Outcome Measures
NameTimeMethod
1 Pain evaluation through VAS <br/ ><br>2 Assessment of adverse eventsTimepoint: 6 weeks, 3, 6, and 12 Months
© Copyright 2025. All Rights Reserved by MedPath